Sigachi Industries Limited officially inaugurated its new state-of-the-art Research and Development (R&D) Center in Hyderabad on June 18, 2025. This advanced facility is designed to consolidate API development and analytical capabilities under one roof, aiming to accelerate product development and enhance the company's responsiveness to global regulatory demands.

Key objectives of the Hyderabad R&D Center include:

• Strengthening API development and regulatory alignment by integrating advanced systems for seamless synthesis, analytics, and global filings.
• Fueling pipeline growth through a targeted investment of up to USD 1 million (approximately ₹8.3 crore) to support priority APIs and complex intermediates.
• Effectively focusing resources by aligning the pharma product portfolio to strategic therapeutic segments.
• Empowering a high-impact research team to lead development efforts for global markets.

Commenting on this development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, stated that the R&D Center is a "strategic asset" that will significantly strengthen the company's development capabilities and enable a swift response to market needs. He added that it reflects Sigachi's focus on building operational depth and creating long-term value for its customers, partners, and stakeholders in the evolving global pharmaceutical environment.